Shares rebound from Monday’s $90b wipeout; oil back to $US90 after earlier surge toward $120; Fortescue completes Alta buy; Air New Zealand axes guidance over conflict. Follow live.
ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS ...
'Thousands more people today can make memories, reach milestones, and spend precious time with their loved ones' ...
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...
Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...
In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...
Huge improvements in prevention, diagnosis and treatment have driven the fall, Cancer Research UK says ...
Cancer death rates in the UK have hit a historic new low, according to data. The charity Cancer Research UK, which analysed ...
Cancer death rates in the UK have fallen to a historic new low, Cancer Research UK has announced. The charity, which analysed ...
Researchers found men who ejaculated more often had fewer prostate cancer diagnoses, pointing to a possible biological ...
The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate cancer imaging agent, aimed at improving scanning access through increased production ...
Among young adults, first ST-segment elevation myocardial infarction (STEMI) in-hospital mortality increased from 2011 to 2022, according to a study published ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results